SCOPE X: Why Clinical Trials Still Need an Operational Conductor

Full interview summary

In a recent video interview with Applied Clinical Trials, Abraham Gutman, founder and CEO of AG Mednet, discussed the concept of operational architecture for AI in clinical trials, drawing on key themes from his presentation at the SCOPE X conference. He opened by tracing the industry's longstanding strength in data capture—from the EDC renaissance of the late 1990s through today's proliferation of eCOA, ePRO, and related systems—and argued that while the industry has mastered collecting and storing data, it has never fully developed the infrastructure needed to act on it. Using the analogy of an orchestra performing without a conductor, Gutman framed the missing layer as execution architecture: the decision workflows that govern how information moves between teams, across organizations, and through the handoffs where clinical trials most often break down.

He went on to describe how the right infrastructure changes the role of human experts, distinguishing between rote but reasoning-intensive activities—like PHI redaction and document QA—that AI can handle with a high degree of objectivity, and true decision-making activities that require human judgment and cannot be delegated. His argument was not that AI replaces people, but that offloading the former frees the latter to focus on what actually matters. He illustrated this with an analogy to the US interstate highway system, positioning the operational architecture as the road infrastructure that makes it possible to connect AI capabilities at the right points in the right sequence, rather than deploying them in isolation with no clear on-ramp or off-ramp.

Gutman closed with pointed takeaways from his SCOPE X session, cautioning against what he described as an overcorrection in the industry's enthusiasm for agentic AI. While he endorsed the technology's potential, he pushed back firmly on claims that armies of agents could effectively run entire clinical trials with minimal human oversight, arguing that clinical trials involve human variability and judgment requirements that software-driven debugging analogies simply do not capture. His closing argument: architecture is the entry point for AI to fulfill its promise in life sciences, and without it, even the most powerful AI capabilities remain untethered and underutilized.